Lucinactant
- Generic Name
- Lucinactant
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 825600-90-6
- Unique Ingredient Identifier
- 5BSH2G9BH8
- Background
Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components. FDA approved on March 6, 2012.
- Indication
Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
- Associated Conditions
- -
- Associated Therapies
- -
Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 16
- Registration Number
- NCT00934362
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.